<DOC>
	<DOCNO>NCT00191308</DOCNO>
	<brief_summary>The main purpose study pemetrexed combined cisplatin use neoadjuvant chemotherapy ( 2 3 cycle ) participant operable non-small cell lung cancer ( NSCLC ) look various gene present participant ' blood tumor tissue see link level change gene participant lung cancer respond pemetrexed cisplatin treatment .</brief_summary>
	<brief_title>Molecular Profiling Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>pathologic documentation nonsmall cell lung cancer ( NSCLC ) tumor must accessible bronchoscopy tumor tissue sample collection patient must lung cancer clinical stage IB , II , IIIA Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 patient must receive prior systemic chemotherapy radiation therapy NSCLC ( prior resection lung allow provide least 5 year elapse prior surgery enrolment ) bronchoalveolar carcinoma stage IIIA tumor involve superior sulcus ( Pancoast tumor ) pregnant breast feeding patient patient receive treatment within last 30 day drug receive regulatory approval indication time study entry patient history presence malignancy except situ carcinoma skin prior malignancy treat 5 year without recurrence ( exclude melanoma , breast cancer hypernephroma ) unwillingness take folic acid vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>